Abstract
Background: Polycystic ovary syndrome (PCOS) is commonly associated with insulin resistance (IR), hyperinsulinemia, and dyslipidemia, which play a role in the development of endothelial dysfunction and promote the early onset of cardiovascular diseases. The aim of this study was to evaluate the clinical importance of pentraxin-3 levels in PCOS patients. Methods: Forty-five female patients diagnosed with PCOS according to the 2003 Rotterdam criteria and 42 healthy women were included in the study. All women studied were tested within 3 and 5 days of their menstrual cycle. Ultrasonographic evaluation of each patient was first conducted using the suprapubic method. Serum PTX-3, endothelin 1 (ET-1), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and nitric oxide levels were measured using the enzyme-linked immunosorbent assay method. Results: Pentraxine-3 (PTX-3) levels in the patient group were significantly lower than those in the control group (p < 0.05). PTX-3 levels in the group with hirsutism were significantly higher than those in the nonhirsutism group (p < 0.05). Homeostatic model assessment for IR (HOMA-IR) levels in the patient group were significantly higher than those in the control group (p < 0.01). A weak negative correlation was found between PTX-3 and HbA1c levels. The accuracy rate of the PTX-3 test in distinguishing patients and nonpatients was moderate with a 0.634 area-under-the-curve value. Conclusions: During the follow-up of patients with PCOS, a decrease in serum PTX-3 levels associated with hirsutism and IR may be observed.
Highlights
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women, with an estimated prevalence of 4–12% worldwide [1]
The control group comprised women who applied to the same hospital with problems that required counseling, but for whom PCOS was not diagnosed after clinical examination
When comparing hormonal measurement levels, we observed that only the levels of luteinizing hormone (LH) in the participants were statistically significantly different (p < 0.05)
Summary
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women, with an estimated prevalence of 4–12% worldwide [1]. Recent data have shown an increased prevalence of cardiovascular disease (CVD) in women with PCOS [2,3]. Patients with PCOS are at risk of developing CVD from an increase in hypertension and dyslipidemia [4]. When metabolic desorders (insulin resistance, hiperinslunemi, dyslipidemia) coexist with PCOS, they may cause the development of endothelial dysfuntion and early onset of CVD [5,6]. Polycystic ovary syndrome (PCOS) is commonly associated with insulin resistance (IR), hyperinsulinemia, and dyslipidemia, which play a role in the development of endothelial dysfunction and promote the early onset of cardiovascular diseases. PTX-3 levels in the group with hirsutism were significantly higher than those in the nonhirsutism group (p < 0.05). Conclusions: During the follow-up of patients with PCOS, a decrease in serum PTX-3 levels associated with hirsutism and IR may be observed
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical and Experimental Obstetrics & Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
